Diagnostic evaluation of the BD Affirm VPIII assay as a point-of-care test for the diagnosis of bacterial vaginosis, trichomoniasis and candidiasis
| Autor: | Fazana Dessai, Makandwe Nyirenda, Nathlee Abbai, Motshedisi Sebitloane |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
medicine.medical_specialty Point-of-care testing Point-of-Care Systems education Trichomonas Trichomonas Infections Dermatology Diagnostic evaluation medicine.disease_cause 03 medical and health sciences South Africa 0302 clinical medicine Pregnancy Internal medicine Candida albicans Prevalence Medicine Humans Pharmacology (medical) 030212 general & internal medicine Health risk 0303 health sciences Trichomoniasis biology 030306 microbiology business.industry Public Health Environmental and Occupational Health Candidiasis Vaginosis Bacterial medicine.disease biology.organism_classification humanities Infectious Diseases Trichomonas vaginalis Female Bacterial vaginosis business |
| Zdroj: | International journal of STDAIDS. 31(4) |
| ISSN: | 1758-1052 |
| Popis: | Untreated sexually transmitted infections and bacterial vaginosis (BV) pose a serious health risk to mother and child. Limited data exist on the use of the BD Affirm™ VPIII assay as a point-of-care test (POCT). The performance of the BD Affirm™ VPIII assay was compared with the BD Max™ vaginal assay for the diagnosis of BV, Trichomonas vaginalis (TV) and Candida spp. A total of 273 pregnant women were enrolled in this study and had provided two self-collected vaginal swabs. Sensitivity, specificity, positive predictive value, negative predictive value and prevalence were calculated. The prevalence of BV, candidiasis and trichomoniasis was 49.4, 57.2 and 10.3%, respectively. The BD Affirm™ VPIII assay showed a moderate sensitivity (79.8%) and a moderate specificity (80.3%) for diagnosing BV in all participants. The BD Affirm™ VPIII assay had an excellent specificity for Candida spp. and TV of 97.4 and 100%, respectively; however, the assay exhibited poor sensitivities of 52.9 and 46.4%, respectively. This study was the first to report on the performance of the BD Affirm™ VPIII assay as a POCT in an antenatal population. The assay was found to be unsuitable as a screening test for vaginal infections in pregnancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|